Keryx Biopharmaceuticals is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and renal disease. Co. is developing KRX-0401 (perifosine), an oral anti-cancer agent in Phase 3 clinical development for both refractory advanced colorectal cancer and relapsed / refractory multiple myeloma, and in Phase 1 and Phase 2 clinical development for several other tumor types. Co. is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound in Phase 3 clinical development as a treatment for hyperphosphatemia (elevated phosphate levels) in patients with end-stage renal disease on dialysis.
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel
from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you
agree to the following Full Disclaimer & Terms of Service. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20
minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.